exist that antagonize this function. Among the negative regulators of TGF-β signaling, I-Smads (ie, Smad6 and Smad7), Smad ubiquitination regulatory factors (Smurfs), TG-interacting factor (TGIF), and Ski-related novel protein N (SnoN) are direct target genes for TGF-β signaling and contribute to negative feedback loops (1, 5) .
Transmembrane prostate androgen-induced RNA (TMEPAI), alternatively termed PMEPA1, STAG1, ERG1.2, or N4wbp4, has been reported to be induced by testosterone or its derivatives and to be implicated in tumorigenesis (6) (7) (8) . The transcript of TMEPAI was recently shown to be induced by TGF-β (9-11). TMEPAI is a type Ib transmembrane protein containing two PY motifs that can interact with HECT-type E3 ubiquitin ligases.
TMEPAI has been reported to be involved in p53-mediated apoptosis (12) and cell growth inhibition (10). However, the mechanism of its action and physiological function is not fully understood. Here, we show that TMEPAI has an essential function in negative regulation of TGF-β signaling in mammalian cells as well as in Xenopus embryos.
Results

TMEPAI is a direct target gene of the TGF-β signal.
We first examined if TMEPAI is indeed a direct target gene of TGF-β signaling. TGF-β potently stimulated TMEPAI expression in AML cells (Fig. 1a) . To explore if TMEPAI is a direct target gene of TGF-β signaling, the cells were treated for 2 h with cycloheximide (CHX) 1 h prior to TGF-β stimulation. As seen in Fig. 1b , the expression of TMEPAI mRNA by TGF-β was elevated in the presence of CHX, indicating that de novo protein synthesis is not required for this response. Thus, TMEPAI is an immediate-early response gene for TGF-β signaling.
Consistent with induction of TMEPAI mRNA by TGF-β, the expression of TMEPAI TMEPAI perturbs TGF-β signaling. I-Smads, Smurfs, SnoN, and TGIF involved in a negative feedback loop that controls TGF-β responses are immediate-early response genes for TGF-β signaling (1, 5) . To investigate if TMEPAI modulates cellular responsiveness to TGF-β, we tested the effect of TMEPAI on the Smad-driven transcriptional (SBE) 4 -luc reporter (17). TMEPAI dose-dependently inhibited TGF-β-induced activation of the (SBE) 4 -luc reporter, but did not affect BMP-induced (SBE) 4 -luc activity (Fig. 2a) . Since TMEPAI is a type Ib transmembrane protein that might be localized to plasma membrane, TMEPAI might exert its negative role on TGF-β/Smad signaling by interfering with R-Smad phosphorylation. To test this possibility, we transfected Smad2 or Smad3 together with constitutively active TβRI, alternatively termed constitutively active ALK5 (ALK5ca), into COS7 cells. Then, immunoprecipitates with anti-Flag antibody were blotted using anti-phospho Smad antibodies (18). TMEPAI markedly reduced phosphorylation of both Smad2 and Smad3 upon ALK5 activation ( Fig. 2b and c) .
Similarly, TMEPAI also blocked activin type I receptor (ALK4)-induced Smad2 phosphorylation (Fig. 2d) . On the other hand, BMP type I receptor (ALK6)-induced Smad1 phosphorylation was not influenced by TMEPAI ( Supplementary Fig. 1b ). Three variants of the human TMEPAI counterpart have been reported (Supplementary Fig. 2a) .
Two possess the transmembrane domain (TM), whereas the third is deficient of TM. Like mouse TMEPAI, all of the human variants could block TGF-β-induced reporter activity and Smad2 phosphorylation ( Supplementary Fig. 2b and c) . Thus, all of the human TMEPAI isoforms can inhibit TGF-β signaling despite the inhibitory ability of each isoform being unequal. In addition, there are no functional differences between mouse and human TMEPAI.
To further confirm the significance of TMEPAI in TGF-β signaling, gain-of function and loss-of function studies were performed. Overexpression of TMEPAI in NMuMG cells using an adenoviral expression system prevented cells from producing PAI-1, a TGF-β direct target gene, upon TGF-β stimulation, whereas TMEPAI(4A), a non-functional TMEPAI mutant (see Fig. 4e-h ), did not affect production of PAI-1 by TGF-β (Fig. 2e) . Conversely, siRNAs corresponding to mouse TMEPAI were introduced into NMuMG cells, and ALK5ca-induced PAI-1 expression was then measured. As expected of a negative role of TMEPAI in TGF-β signaling, PAI-1 produced by NMuMG cells upon ALK5 activation was further enhanced after treatment of cells with TMEPAI-specific siRNA (Fig. 2f) . Consistent with the increase in ALK5ca-induced PAI-1 production using TMEPAI siRNA, TMEPAI-specific knockdown augmented ALK5ca-mediated Smad2 phosphorylation (Fig. 2g,h ). These results indicate that TMEPAI is a physiologically critical molecule for attenuating TGF-β signaling.
TMEPAI interacts with Smad2 and Smad3. I-Smads are known to prevent R-Smads from being phosphorylated by active ALK5 kinase due to its competition with R-Smads for binding to active ALK5 (13). Compared with Smad7, TMEPAI only marginally interacts with the TGF-β receptor complex ( Supplementary Fig. 3a) , suggesting that TMEPAI perturbs TGF-β signaling by a mechanism that is distinct from the antagonistic action of Smad7.
Next, we examined the possibility that TMEPAI can directly interact with Smad proteins. Results shown in Fig. 3a revealed that TMEPAI binds to R-Smads (Smad2 and Smad3), but not to Smad4 and Smad7. In addition, we found that R-Smads do not need to be activated for TMEPAI interaction. However, we were unable to distinguish phosphorylated R-Smads from non-phosphorylated R-Smads in this experiment because TMEPAI blocks R-Smad phosphorylation ( Fig. 2b and c) . Therefore, to address this issue further, we prepared lysates from cells transfected with either Smad2 alone or with Smad2 and ALK5ca. Subsequently, each lysate was mixed with lysate prepared from cells transfected with TMEPAI alone and then immunoprecipitated with anti-Flag antibody and analyzed by Western blotting with anti-V5 antibody. As seen in Figure 3b , TMEPAI bound equally to both non-phosphorylated and phosphorylated Smad2. We also explored if TMEPAI interacts with SARA. However, although association between SARA and Smad2 could be seen, no obvious interaction was detected ( Supplementary Fig. 3b ).
After TGF-β stimulation, phosphorylated Smad2 can form a heteromeric complex with Smad4 and then enter the nucleus to regulate target gene expression (1) . Since TMEPAI blocks TGF-β-induced Smad2 phosphorylation, we speculated that TMEPAI may perturb the Smad2/Smad4 interaction upon receptor activation. Indeed, ectopic expression of TMEPAI was found to inhibit complex formation between Smad2 and Smad4 upon ALK5 activation (Fig. 3c) . To show the physiological significance of the association between TMEPAI and Smad2, we investigated the endogenous interaction of TMEPAI with Smad2 in NMuMG cells. As TMEPAI expression in the absence of TGF-β is low, the cells were treated with TGF-β for 8 h (Fig. 1c) . As expected, TMEPAI interacted with Smad2 in non-transfected NMuMG cells (Fig. 3d) . The latter interaction is specific as TMEPAI could not interact with the closely related Smad1 (Supplementary Fig.   1c ). Taken together, we concluded that TMEPAI induced by TGF-β preferentially associates with TGF-β/activin R-Smads (ie, Smad2 and Smad3) to inhibit ALK5-mediated R-Smad phosphorylation.
A SIM domain is essential for TMEPAI to block the TGF-β signal. We next explored which domain(s) of TMEPAI contributes to its inhibitory effect on TGF-β signaling.
TMEPAI possesses two PY motifs that interact with E3 ubiquitin ligases containing WW domains (19). However, all of the TMEPAI mutants lacking the PY motifs (TMEPAIΔPY1, TMEPAIΔPY2, and TMEPAIΔPY) retained their inhibitory ability of TGF-β signaling ( Supplementary Fig. 4a-c) . Like human TMEPAI isoform C ( Supplementary Fig. 2b and c), TMEPAI lacking its transmembrane domain (TMEPAIΔTM) (Supplementary Fig. 4a ), which is mislocalized in cytosols (data not shown), could also inhibit, albeit more weakly, the TGF-β-induced reporter activity ( Supplementary Fig. 4b ). Thus, the integration of TMEPAI in the membrane is not required for its inhibitory effect on TGF-β signaling. To further analyze the domain that is involved in blocking TGF-β signaling, three deletion mutants of TMEPAI from its C-terminus were generated (Fig. 4a) (Fig. 4f) .
Consistently, TMEPAI(4A) could not block TGF-β-induced Smad2 phosphorylation ( Fig.   4g ) and reporter activity ( TMEPAI inhibits activin-induced mesoderm formation in Xenopus embryos. On the basis of the studies in cultured mammalian cells described above, we predicted that TMEPAI may inhibit activin signaling during Xenopus embryogenesis. For that purpose, we isolated a Xenopus counterpart for mammalian TMEPAI. Xenopus TMEPAI shares 70% and 66% amino acid sequence identity with human and mouse TMEPAI, respectively (Supplementary Fig. 6 ). However, the TM, SIM and PY motifs in TMEPAI of the 3 species are almost identical. We analyzed patterning phenotypes caused by overexpression of Xenopus TMEPAI (xTMEPAI) in Xenopus embryos. When the endogenous activin signaling pathway is inactivated in early Xenopus embryos, mesoderm fails to form (23,24).
Similarly, microinjection of mRNA encoding xTMEPAI into the dorsal marginal zone (DMZ) of 4-cell embryos inhibited mesoderm formation. Specifically, head and tail structures were absent or severely deficient in 96% of the injected embryos (n=25) (Fig.   6a ). On the other hand, the injected embryos showed hardly any deficiencies when the same amount of xTMEPAI mRNA was injected into the animal pole or the ventral marginal zone (VMZ) (data not shown). Activin is one of the endogenous mesoderm-inducing molecules (25). To examine whether xTMEPAI blocks activin-induced mesoderm formation in vivo, we performed the Xenopus animal cap assay.
Activin induced expression of Xbra, a pan-mesodermal marker, and gsc, a dorsal mesodermal marker. When xTMEPAI mRNA was injected into the animal poles of 2-cell embryos, xTMEPAI dose-dependently blocked the expression of Xbra and gsc markers (Fig. 6b) . Moreover, the injection of xTMEPAI mRNA into the DMZ of 4-cell embryos also prevented the endogenous expression of both Xbra and gsc markers in a dose-dependent manner (Fig. 6c ). These results demonstrate that xTMEPAI can perturb activin-mediated mesoderm induction.
To further consolidate the inhibitory effect of xTMEPAI in Xenopus embryos, we examined the molecular effects of xTMEPAI knockdown by monitoring expression of activin-induced marker genes in animal cap cells. As expected, the injection of xTMEPAI morpholino oligonucleotide (TMEPAI MO) augmented expression of Xbra and gsc in comparison with that of the control MO (scramble MO) or the mock-injected (Fig. 6d) .
Above evidence supports the view that TMEPAI blocks the activin signaling pathway in Xenopus embryo.
Discussion
Positive and negative signals are equally critical for regulation of the TGF-β/Smad signaling pathway (1) . Disruption of the balance between positive and negative regulation in TGF-β signaling can lead to various diseases (3). We have herein presented evidence demonstrating that TMEPAI, a transmembrane protein, is implicated in termination of TGF-β signaling. Since TMEPAI is a direct early target gene for TGF-β signaling, we conceived the possibility that TMEPAI acts like I-Smads in a negative feedback loop. As expected, TMEPAI negatively controls the TGF-β signaling pathway. An interesting question is why TMEPAI appears to be responsible for inhibition of TGF-β or activin signaling, but not that of BMP signaling. Although we initially thought that the PY motifs in TMEPAI are involved in its inhibitory effects on TGF-β signaling, our mutants lacking the PY motifs displayed inhibitory actions comparable with those of wild-type TMEPAI ( Supplementary Fig. 4a-c) . Indeed, the SIM domain in TMEPAI (PPNR) was a critical domain in preventing TGF-β signaling. As in a previously described experiment that used the SIM domain in Mixer (26), the SIM domain in TMEPAI also showed almost the same affinity to both non-phosphorylated and phosphorylated Smad2. Thus, TMEPAI can trap not only non-phosphorylated Smad2 and Smad3 but also TβRI kinase-activated Smad2 and Smad3 after ligand stimulation in order to terminate TGF-β signaling efficiently.
Binding of Smad2 and Smad3 to TMEPAI is mutually exclusive with binding to SARA.
Consequently, TMEPAI sequesters Smad2 and Smad3 from SARA so that it cannot recruit Smad2 and Smad3 to the activated TGF-β receptor complex (Fig. 7) . It has been reported that like SARA, Hgs, which possesses a FYVE domain, also has the attribute of acting as a In conclusion, TMEPAI is a novel type of TGF-β/activin-specific blocker which preferentially perturbs recruitment of Smad2 or Smad3 to TβRI by SARA. Thus, TMEPAI can limit the duration of Smad phosphorylation in a negative feedback mechanism. Loss of TGF-β responsiveness via genetic hereditary mutation, somatic mutation, or aberrant expression of components for TGF-β signaling is linked to tumorigenicity or inheritable disorders. From this point of view, TMEPAI might become a potential target for therapeutic intervention. Cell Culture -HepG2, NMuMG, NIH3T3, AML, and COS7 cells were cultured in Dulbecco's modified Eagle's medium (Sigma) containing 10% fetal calf serum (Bio-west) and 1x MEM non-essential amino acids (Invitrogen). MCF10A1 and its derivatives were maintained by the method described previously except for use of 5 μM forskolin instead of cholera toxin (15).
Materials and Methods
Expression Plasmids
Immunohistochemistry -The paraffin-embedded tissues were sectioned to a 3 μm thickness, deparaffinized in xylene, rehydrated in graded ethanol solution, and immersed in citrate-NaOH buffer (10 mM sodium citrate, pH 7.2) for 20 min at 115˚C to restore antigenicity. The rehydrated sections were stained with hematoxylin and eosin, or 
Microinjection of synthetic mRNA and RT-PCR analysis for Xenopus embryos-
Unfertilized eggs were collected and fertilized in vitro as previously described (38) . The embryos were subsequently dejellied using 3% cysteine. Capped mRNAs for each protein to be tested were synthesized from linearized constructs using the mMESSAGE mMACHINE SP6 kit (Ambion). For animal cap assays, mRNAs were injected into the animal poles of 2-cell-stage embryos. Injected embryos were kept in 3% Ficoll/0.1 x Steinberg's solution as previously described (39) . Animal cap explants were dissected with hair knives at stages 8 to 9. For ventral induction, synthetic mRNAs were injected into two dorsal blastomeres at the 4-cell stage. Embryos were examined for phenotype at the tadpole stage. Animal caps were collected from sibling embryos at stage 12, and total RNA was extracted using TRIzol (Gibco/BRL) according to the manufacturer's instructions. cDNA was synthesized from extracted RNAs as previously described (39) for RT-PCR analysis.
PCR was performed with the oligonucleotide primer pairs: Xbra, PAI-1 production was normalized using the intensity of the band corresponding to β-actin. 
